Nephris Srl
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nephris Srl - overview
Established
2021
Location
Milan, -, Italy
Primary Industry
Biotechnology
About
Founded in 2021 by Paolo Fiorina and Francesca D’Addio, and based in Italy, Nephris Srl operates as a pre-clinical-stage biotech company focused on new targets of kidney disease progression. In April 2022, Nephris Srl raised EUR 3 million in seed funding from investor Sofinnova Partners. The company offers research and development of therapies in diabetic nephropathy that, can improve kidney function. The company deals with patients suffering from type 1 and type 2 diabetes and offers new treatments that could prevent, treat, and reverse diabetic kidney disease.
The platform also provides research and treatment for chronic kidney diseases.
Current Investors
Sofinnova Partners
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Biopharmaceuticals
Website
www.nephris.com/
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.